The intervention showed no clear difference in withdrawals due to adverse events (low certainty).
Certolizumab pegol probably leads to higher clinical remission compared with placebo (moderate certainty).
Certolizumab pegol probably leads to higher clinical response compared with placebo (moderate certainty).
Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
It is very uncertain whether elemental changes remission rate ‐ Intention to treat compared with non‐elemental enteral feeds (very low certainty).
It is very uncertain whether elemental changes adverse events compared with non‐elemental enteral feeds (very low certainty).
It is very uncertain whether elemental changes withdrawal due to adverse events compared with non‐elemental enteral feeds (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT adult studies compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ ITT pediatric studies compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes remission rate ‐ per‐protocol ‐ pediatric studies compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes adverse events compared with corticosteroids (very low certainty).
It is very uncertain whether enteral nutrition changes withdrawal due to adverse events compared with corticosteroids (very low certainty).
It is very uncertain whether elemental formula supplements changes relapse compared with polymeric formula supplements (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether enteral nutrition changes relapse compared with 6‐MP (very low certainty).